Brian J. Capaldo, Ph.D.

Brian J. Capaldo, Ph.D.
Staff Scientist

Dr. Capaldo's research focuses on identifying best practices in bioinformatics and computational biology and applying these to biological problems to generate testable hypotheses in the field of prostate cancer. 

Areas of Expertise

1) bioinformatics, 2) RNA sequencing, 3) single cell, 4) computational epigenomics, 5) computational high parameter cytometry

Contact Info

Brian J. Capaldo, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 37, Room 1066A
Bethesda, MD 20892
Ph: 240-760-6606
capaldobj@nih.gov

My research interests are focused on the integrative statistical analysis of high-throughput molecular assays, specifically sequencing data and high-dimensional single cell data. Much of my work has been devoted to the analysis and interpretation of the transcriptomic response to perturbation of signaling through the use of single- and combination-targeted therapies in prostate cancer, as well as identifying molecular phenotypes of adenocarcinoma, neuroendocrine prostate cancer, and mechanisms of castrate-resistant prostate cancer.

NIH Scientific Focus Areas:
Cancer Biology, Computational Biology, Genetics and Genomics
View Dr. Capaldo's Google Scholar page.

Selected Key Publications

  1. Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.
    PLoS One. 10(9): e0138210, 2015. [ Journal Article ]
  2. Cox KM, Commins SP, Capaldo BJ, Workman LJ, Platts-Mills TAE, Amir ED, Lannigan JA, Schuyler AJ, Erickson LD.
    Clin Exp Allergy. 49(5): 615-625, 2019. [ Journal Article ]

Brian J. Capaldo received his B.S. in molecular and cellular biology from Johns Hopkins University, where he undertook part of the Synthetic Yeast Genome Project under Dr. Jef Boeke. He went on to the University of Virginia (UVA) to obtain a Ph.D. in the lab of Stefan Bekiranov, where he studied computational biology focusing on identifying mechanisms of sensitivity and resistance to single and combinatorial therapy in melanoma and B cell malignancies. After his defense, he joined the UVA School of Medicine Core Facilities, supporting the Mass Spectrometry, Flow Cytometry, and Bioinformatics Cores.

Dr. Capaldo was drawn to the Laboratory of Genitourinary Cancer Pathogenesis to continue his work in molecular phenotyping and identification of mechanisms of resistance to targeted therapy in cancer. He joined in April of 2018 as a Bioinformatics Scientist.